Onco-Innovations Balance Sheet

Financials in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jan '26 Jan 31, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023
Cash & Equivalents	0.51	1.11	0.45	0.02
Cash & Short-Term Investments	0.51	1.11	0.45	0.02
Cash Growth	14.78%	148.24%	2318.62%	-
Accounts Receivable	-	0.05	-	-
Other Receivables	0.03	0.04	-	-
Receivables	0.03	0.09	-	-
Prepaid Expenses	0.23	1.01	-	-
Total Current Assets	0.84	2.22	0.45	0.02
Total Assets	0.84	2.22	0.45	0.02
Accounts Payable	0.4	0.38	0.09	-
Accrued Expenses	0.05	0.03	0.04	-
Total Current Liabilities	0.45	0.41	0.13	-
Total Liabilities	0.45	0.41	0.13	-
Common Stock	15.62	8.68	0.05	0
Retained Earnings	-16.94	-8.63	-0.13	-0
Comprehensive Income & Other	1.71	1.75	0.4	0.02
Shareholders' Equity	0.39	1.81	0.32	0.02
Total Liabilities & Equity	0.84	2.22	0.45	0.02
Net Cash (Debt)	0.51	1.11	0.45	0.02
Net Cash Growth	14.78%	148.24%	2318.62%	-
Net Cash Per Share	0.01	0.03	0.13	-
Filing Date Shares Outstanding	59.43	53.83	38.38	-
Total Common Shares Outstanding	57.55	50.71	4.38	-
Working Capital	0.39	1.81	0.32	0.02
Book Value Per Share	0.01	0.04	0.07	-
Tangible Book Value	0.39	1.81	0.32	0.02
Tangible Book Value Per Share	0.01	0.04	0.07	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.